<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1569">
  <stage>Registered</stage>
  <submitdate>22/12/2003</submitdate>
  <approvaldate>22/12/2003</approvaldate>
  <actrnumber>ACTRN12606000519550</actrnumber>
  <trial_identification>
    <studytitle>Chemoradiotherapy in patients with localised lung cancer</studytitle>
    <scientifictitle>Trans Tasman Radiation Oncology Group (TROG) 03.07 - A randomised phase II study of two regimens of palliative chemoradiation therapy (Vinorelbine and cisplatin OR Gemcitabine) in the management of locally advanced and metastatic non-small lung cancer to improve response rate.</scientifictitle>
    <utrn />
    <trialacronym>TROG 03.07</trialacronym>
    <secondaryid>ClinicalTrials.gov: NCT00193921</secondaryid>
    <secondaryid>National Clinical Trials Registry: NCTR464</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Locally advanced and metastatic non-small cell lung cancer.</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm A: External beam radiation, 40Gy in 20 fractions/5 times per week plus Vinorelbine, IV, 25mg/m square, days 1, 8, 22 and Cisplatin 20mg/m cubed, IV, weekly. Subjects receive this treatment over 1 month (4 weeks).</interventions>
    <comparator>Arm 2: External Beam radiation. 30Gy in 15 fractions/5 times per week plus Gemcitabine, 200mg, IV days 1, 8 and 15. Subjects receive this treatment over 3 weeks.</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>1. Objective response rate (RECIST criteria).</outcome>
      <timepoint>Response will be assessed at 6 weeks post the completion of chemoradiotherapy. </timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>2. Symptomatic response rate.</outcome>
      <timepoint>Will be assessed at baseline, at 3 and 6 weeks post chemoradiotherpay and at follow up every 3 months until death. </timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>3. The feasibility and problems encountered with protocol compliance.</outcome>
      <timepoint>When study is complete Expected duration is 2 years. </timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>4. Toxicity of both treatments.</outcome>
      <timepoint>Weekly during chemoradiotherapy, weekly for the first 3 weeks after and at the 6 week mark post chemoradiotherapy and then every 3 months until death.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. Progression free survival.</outcome>
      <timepoint>Time interval from date of randomisation to objective documentation of tumour progression or death due to tumour progression. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Quality of Life.</outcome>
      <timepoint>Baseline, at 3 and 6 weeks post chemoradiotherpay and at follow up every 3 months until death.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Histologically or cytologically proven non-small cell lung cancer.- Planned high dose palliative radiation therapy for locoregional control. Examples include patients with:  a) Stage I  IIIB disease with: -disease technically unsuitable for radical therapy, or -weight loss in excess of 10%, or -concurrent medical illness  b)Patients found to have a locally advanced thoracic disease suitable for radical therapy but on work up are found to have a Flurodeoxyglucose-Positron Emission Tomography (FDG-PET) only solitary metastasis.- All potential patients, prior to registration, must be reviewed at a multidisciplinary lung oncology meeting attended by medical oncologists, radiation oncologists and radiologists.- No prior radiotherapy or chemotherapy for non-small cell lung cancer. - European Cooperative Ooncology Group  performance status 0, 1.- Adequate hepatic, bone marrow and renal function.- If patient is female of child bearing potential, she must not be pregnant or lactating. Males and females of reproductive potential must practise adequate contraception.- Written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patient unable to receive all therapy as an outpatient.- Significant medical conditions which in the opinion of the investigator would compromise the planned delivery of the chemotherapy and radiotherapy or which may be potentially exacerbated by these modalities.- History of any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix) unless in complete remission and off all therapy for that cancer for at least 5 years.- Receiving treatment with another investigational agent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation</concealment>
    <sequence>Simple randomisation by computer</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/02/2003</anticipatedstartdate>
    <actualstartdate>4/12/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate>14/07/2007</actualenddate>
    <samplesize>80</samplesize>
    <actualsamplesize>84</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Bryan Burmeister</primarysponsorname>
    <primarysponsoraddress>Princess Alexandra Hospital Oncology Services Ipswich Road Woolloongabba QLD 4102</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Multi-State Cancer Council Grant (Australian Capital Territory, Queensland)</fundingname>
      <fundingaddress>Level 5, 20 Allara St Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Trans Tasman Radiation Oncology Group (TROG)</sponsorname>
      <sponsoraddress>Edith St Waratah NSW 2298</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Using radiotherapy and chemotherapy together works better in locally advanced lung cancer than using either treatment alone but has worse side effects.  Many people are not fit enough to have these treatments given in the standard way.  This study will test the feasibility and activity of two gentler ways of combining them.</summary>
    <trialwebsite>www.trog.com.au</trialwebsite>
    <publication>Burmeister BH, Michael M, Burmeister E, Cox S, Lehman M, Wirth A, Horwood K, Sasso G, Forouzesh B, Ball D. A randomised phase II trial of 2 regimens of moderate dose chemoradiation therapy for patients with non small cell lung cancer not suitable for curative therapy - Trans Tasman Radiation Oncology Study TROG 03.07. J Thorac Oncol. 2011; 6: 2076-2082.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Murray Valley Private Hospital</ethicname>
      <ethicaddress>Wodonga, VIC</ethicaddress>
      <ethicapprovaldate>1/12/2003</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>RadOnc VIC - Frankston Private Hospital</ethicname>
      <ethicaddress>Frankston, VIC</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Premion Tugun - John Flynn Private</ethicname>
      <ethicaddress>Tugun, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Calvary Mater Newcastle</ethicname>
      <ethicaddress>Waratah, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater QRI</ethicname>
      <ethicaddress>South Brisbane, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress>Melbourne, VIC</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital</ethicname>
      <ethicaddress>Wooloongabba, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Townsville Hospital</ethicname>
      <ethicaddress>Townsville, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Bryan Burmeister</name>
      <address>Princess Alexandra Hospital
Oncology Services
Ipswich Road
Woolloongabba QLD 4102</address>
      <phone>+61 7 3240 6584</phone>
      <fax />
      <email>Bryan_Burmeister@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Sharon Cox</name>
      <address>Princess Alexandra Hospital
Oncology Services
Ipswich Road
Woolloongabba QLD 4102</address>
      <phone>+61 7 3240 2007</phone>
      <fax />
      <email>Sharon_Cox@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Erin Nolan</name>
      <address>Department of Radiation Oncology Locked Bag 7 Hunter Region Mail Centre NSW 2310</address>
      <phone>+61 2 4014 3912</phone>
      <fax>+61 2 4014 3902</fax>
      <email>Erin.Nolan@trog.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Bryan Burmeister</name>
      <address>Princess Alexandra Hospital Oncology Services Ipswich Road Woolloongabba QLD 4102</address>
      <phone>+61 7 3240 6584</phone>
      <fax />
      <email>Burmeister@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>